Uma Ramesh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Uma Ramesh has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Dan Yaniv
Department of Otolaryngology-Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Israel
2 shared publications - Elizabeth Chiang
School of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publications - Haleigh Stafford
School of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publications - Jane Buell
School of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publications - Maria Feucht
Department of Otolaryngology‐Head & Neck Surgery University of Kansas Medical Center Kansas City Kansas USA
2 shared publications - Moran Amit
Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2 shared publications
Latest Publications
- 17 February 2025
- Published by Wiley in Head & Neck
- Vol. 47 (7)
Upper Aerodigestive Tract Liposarcoma: Four Cases of a Rare Entity and a Review of the Literature
Background: Liposarcomas involving the upper aerodigestive tract (UADT) are extremely rare. Consequently, consensus regarding the treatment approach and surveillance is not well established.Methods: We present four cases of UADT liposarcoma. All patients presented with either dysphagia or respiratory difficulty and underwent endoscopic examination as part of their diagnostic workup. Surgical excision, either endoscopic or open resection, was performed for all patients.Results: All patients had a pathologic diagnosis of well‐differentiated liposarcoma without nodal or distant disease involvement. One patient underwent complete resection with no recurrences. Another patient experienced several recurrences, and his tumor ultimately underwent rapid disease progression and pathologic transformation into dedifferentiated liposarcoma, necessitating total laryngectomy. Of the two patients with positive surgical margins at their initial resections, one was lost to follow‐up from our institution. The other three patients, including the second patient with positive margins, continue to follow up with endoscopic surveillance at our institution with no evidence of residual disease.Conclusions: UADT liposarcoma is a locally aggressive tumor that may frequently recur. Stringent surveillance is necessary to monitor disease progression, particularly if positive margins are noted during surgical excision. The role of adjuvant therapy has yet to be established.
- 17 February 2025
- Published by Wiley in Head & Neck
- Vol. 47 (7)
Upper Aerodigestive Tract Liposarcoma: Four Cases of a Rare Entity and a Review of the Literature
Background: Liposarcomas involving the upper aerodigestive tract (UADT) are extremely rare. Consequently, consensus regarding the treatment approach and surveillance is not well established.Methods: We present four cases of UADT liposarcoma. All patients presented with either dysphagia or respiratory difficulty and underwent endoscopic examination as part of their diagnostic workup. Surgical excision, either endoscopic or open resection, was performed for all patients.Results: All patients had a pathologic diagnosis of well‐differentiated liposarcoma without nodal or distant disease involvement. One patient underwent complete resection with no recurrences. Another patient experienced several recurrences, and his tumor ultimately underwent rapid disease progression and pathologic transformation into dedifferentiated liposarcoma, necessitating total laryngectomy. Of the two patients with positive surgical margins at their initial resections, one was lost to follow‐up from our institution. The other three patients, including the second patient with positive margins, continue to follow up with endoscopic surveillance at our institution with no evidence of residual disease.Conclusions: UADT liposarcoma is a locally aggressive tumor that may frequently recur. Stringent surveillance is necessary to monitor disease progression, particularly if positive margins are noted during surgical excision. The role of adjuvant therapy has yet to be established.
- 31 January 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (4) , 1318-1327
Sociodemographic and Clinical Determinants of 12‐Month Decision Regret for Head and Neck Cancer Patients
Objective: This study aims to identify factors associated with increased decision regret (DR) 12 months following treatment among head and neck cancer (HNC) patients.Study Design: A retrospective observational cohort study.Setting: Patients with newly diagnosed HNC at an academic tertiary care center from 2018 to 2023.Methods: Data from a patient registry assessing quality of life (QOL), DR, social support, and anxiety at initial diagnosis and 12 months post‐treatment were analyzed. Only patients who completed the decision regret questionnaire at 12 months were included.Results: Among 225 participants, 60% experienced mild DR and 28% reported moderate to severe regret. Stronger regret was associated with advanced disease presentation, free flap reconstructive surgery, chemoradiation, and disease recurrence. Patients with more severe regret had lower QOL at baseline and 12 months, higher anxiety at 12 months, and lower social support at 12 months. Multivariable analysis identified multimodal treatment including radiation (adjusted odds ratio [aOR] 3.67, 95% confidence interval [CI] [1.25‐10.78], P = .018), lower 12‐month social support (aOR 1.03, 95% CI [1.00‐1.05], P = .039), and decreases in QOL (aOR 1.03, 95% CI [1.00‐1.06], P = .024) as independent predictors of increased DR.Conclusion: Treatment involving radiation, lower concurrent social support, and diminished QOL are associated with DR 12 months after treatment. This highlights the potential of interventions aimed at enhancing social support, addressing treatment‐related sequelae, and strengthening shared decision‐making to prevent regret. Further studies are needed to elucidate factors driving regret in HNC patient subgroups and assess the efficacy of proposed mitigative interventions.
- 31 January 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (4) , 1318-1327
Sociodemographic and Clinical Determinants of 12‐Month Decision Regret for Head and Neck Cancer Patients
Objective: This study aims to identify factors associated with increased decision regret (DR) 12 months following treatment among head and neck cancer (HNC) patients.Study Design: A retrospective observational cohort study.Setting: Patients with newly diagnosed HNC at an academic tertiary care center from 2018 to 2023.Methods: Data from a patient registry assessing quality of life (QOL), DR, social support, and anxiety at initial diagnosis and 12 months post‐treatment were analyzed. Only patients who completed the decision regret questionnaire at 12 months were included.Results: Among 225 participants, 60% experienced mild DR and 28% reported moderate to severe regret. Stronger regret was associated with advanced disease presentation, free flap reconstructive surgery, chemoradiation, and disease recurrence. Patients with more severe regret had lower QOL at baseline and 12 months, higher anxiety at 12 months, and lower social support at 12 months. Multivariable analysis identified multimodal treatment including radiation (adjusted odds ratio [aOR] 3.67, 95% confidence interval [CI] [1.25‐10.78], P = .018), lower 12‐month social support (aOR 1.03, 95% CI [1.00‐1.05], P = .039), and decreases in QOL (aOR 1.03, 95% CI [1.00‐1.06], P = .024) as independent predictors of increased DR.Conclusion: Treatment involving radiation, lower concurrent social support, and diminished QOL are associated with DR 12 months after treatment. This highlights the potential of interventions aimed at enhancing social support, addressing treatment‐related sequelae, and strengthening shared decision‐making to prevent regret. Further studies are needed to elucidate factors driving regret in HNC patient subgroups and assess the efficacy of proposed mitigative interventions.
- Open Access
Cutaneous Squamous Cell Carcinoma of the Head and Neck: Pathological Features and What They Mean for Prognosis and Treatment
Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers worldwide, with an incidence that has increased over the past 30 years. Although usually curable with excision, cSCC can become widely metastatic and aggressive with poor outcomes. Whereas the clinical and radiographic extent of any cancer will always guide selection of treatment modality, pathological features of cSCC also play an important role in determining prognosis and, subsequently, the need for further therapy. Therefore, reviewing and summarizing the current literature regarding pathological prognostic indicators of cSCC is essential to improving clinical outcomes. The present literature review yielded depth of invasion, surgical margins, perineural invasion, extranodal extension, lymphovascular invasion, tumor grade, tumor subtype, premalignant lesions, and molecular markers as key prognostic indicators, all with varying recommendations for adjuvant therapy. Notably, some of these factors have not been incorporated into either the American Joint Committee on Cancer staging system (8th edition) or National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for cSCC. This review highlights a need for further research into these prognostic indicators and their role in determining the need for adjuvant treatment in head and neck cSCC.
Open AccessCutaneous Squamous Cell Carcinoma of the Head and Neck: Pathological Features and What They Mean for Prognosis and Treatment
Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers worldwide, with an incidence that has increased over the past 30 years. Although usually curable with excision, cSCC can become widely metastatic and aggressive with poor outcomes. Whereas the clinical and radiographic extent of any cancer will always guide selection of treatment modality, pathological features of cSCC also play an important role in determining prognosis and, subsequently, the need for further therapy. Therefore, reviewing and summarizing the current literature regarding pathological prognostic indicators of cSCC is essential to improving clinical outcomes. The present literature review yielded depth of invasion, surgical margins, perineural invasion, extranodal extension, lymphovascular invasion, tumor grade, tumor subtype, premalignant lesions, and molecular markers as key prognostic indicators, all with varying recommendations for adjuvant therapy. Notably, some of these factors have not been incorporated into either the American Joint Committee on Cancer staging system (8th edition) or National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for cSCC. This review highlights a need for further research into these prognostic indicators and their role in determining the need for adjuvant treatment in head and neck cSCC.
- 18 October 2023
- Published by Wiley in Head & Neck
- Vol. 46 (1) , 29-36
Sinonasal NUT carcinoma: A consecutive case series and systematic review
Background: Sinonasal NUT carcinoma is an extremely rare, lethal malignancy with limited literature.Methods: A case series was conduction of all patients with sinonasal NUT carcinoma at a single institution between 2010 and 2022. Survival and associated were evaluated. A systematic review of the literature was performed.Results: In 12 patients, followed for a median of 1.5 years, the median overall survival (OS) and disease‐specific survival (DSS) were both 14.6 months. Patients with maxillary sinus tumors were 91% more likely to survive (hazard ratio [HR]: 0.094, 95% confidence interval [CI]: 0.011–0.78, p = 0.011). Patients with higher‐stage disease stage had worse OS (stage IVb‐c vs. III‐IVa, p = 0.05). All three patients who were alive with no evidence of disease received induction chemotherapy.Conclusion: For patients with sinonasal NUT carcinoma, the median survival was 15 months but better with lower‐stage and maxillary tumors. Induction chemotherapy may be beneficial.
- 18 October 2023
- Published by Wiley in Head & Neck
- Vol. 46 (1) , 29-36
Sinonasal NUT carcinoma: A consecutive case series and systematic review
Background: Sinonasal NUT carcinoma is an extremely rare, lethal malignancy with limited literature.Methods: A case series was conduction of all patients with sinonasal NUT carcinoma at a single institution between 2010 and 2022. Survival and associated were evaluated. A systematic review of the literature was performed.Results: In 12 patients, followed for a median of 1.5 years, the median overall survival (OS) and disease‐specific survival (DSS) were both 14.6 months. Patients with maxillary sinus tumors were 91% more likely to survive (hazard ratio [HR]: 0.094, 95% confidence interval [CI]: 0.011–0.78, p = 0.011). Patients with higher‐stage disease stage had worse OS (stage IVb‐c vs. III‐IVa, p = 0.05). All three patients who were alive with no evidence of disease received induction chemotherapy.Conclusion: For patients with sinonasal NUT carcinoma, the median survival was 15 months but better with lower‐stage and maxillary tumors. Induction chemotherapy may be beneficial.
- Open Access
Review of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma
It is widely known that tumor cells of basal and squamous cell carcinoma interact with the cellular and acellular components of the tumor microenvironment to promote tumor growth and progression. While this environment differs for basal and squamous cell carcinoma, the cellular players within both create an immunosuppressed environment by downregulating effector CD4+ and CD8+ T cells and promoting the release of pro-oncogenic Th2 cytokines. Understanding the crosstalk that occurs within the tumor microenvironment has led to the development of immunotherapeutic agents, including vismodegib and cemiplimab to treat BCC and SCC, respectively. However, further investigation of the TME will provide the opportunity to discover novel treatment options.
Open AccessReview of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma
It is widely known that tumor cells of basal and squamous cell carcinoma interact with the cellular and acellular components of the tumor microenvironment to promote tumor growth and progression. While this environment differs for basal and squamous cell carcinoma, the cellular players within both create an immunosuppressed environment by downregulating effector CD4+ and CD8+ T cells and promoting the release of pro-oncogenic Th2 cytokines. Understanding the crosstalk that occurs within the tumor microenvironment has led to the development of immunotherapeutic agents, including vismodegib and cemiplimab to treat BCC and SCC, respectively. However, further investigation of the TME will provide the opportunity to discover novel treatment options.